Morgan Stanley Initiates Horizon Pharma With Overweight

Loading...
Loading...
Analysts at Morgan Stanley initiated coverage on
Horizon Pharma PLCHZNP
with a Overweight rating. The target price for Horizon Pharma is set to $38. Horizon Pharma shares have gained 116.45 percent over the past 52 weeks, while the S&P 500 index has surged 9.07 percent in the same period. Horizon Pharma shares rose 0.41 percent to $31.97 in after-hours trading.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...